U.S. Department of Health and Human Services has described opioid receptor modulators reported to be useful for the treatment of pain.

1910 Genetics Inc. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of allergy, cancer, inflammation, autoimmune disease, metabolic diseases, endocrine and neurological disorders.

Zeno Management Inc. has identified antibody-drug conjugates comprising antibodies targeting inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) covalently bound to exatecan derivatives through a linker.

Septerna Inc. has synthesized thyroid-stimulating hormone receptor (TSHR) antagonists reported to be useful for the treatment of hyperthyroidism.

Vandria SA has disclosed urolithin and fluorene derivatives acting as ferroptosis inhibitors and reported to be useful for the treatment of neurodegeneration and inflammatory disorders.

Huntingtin (HTT; HD; mutant) splicing modulators for the treatment of Huntington’s disease have been disclosed in a Biogen Inc. patent.

Purdue Research Foundation, The Brigham and Women's Hospital Inc., the University of California Oakland and University of Utah have developed platinum complexes for the treatment of cyanide poisoning.

Recent Cedilla Therapeutics Inc. patents describe new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer’s disease, hepatic fibrosis, viral infections, inflammatory disorders and polycystic kidney.

Fochon Biosciences Ltd. has identified apoptosis regulator Bcl-2 (D103E mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.

Work at Beijing Earthwise Technology Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.